UNSPSC 51332864: Perphenazine enanthate

This classification denotes an antipsychotic agent with the molecular formula C28H38ClN3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z6RS3DKN8J, chemically known as 2-(4-(3-(2-chlorophenothiazin-10-yl)propyl)piperazin-1-yl)ethanol, heptanoate, but more generally known as perphenazine enanthate, which bears US NIH Compound Identifier 62871. European Medicines Agency schedules perphenazine enanthate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09736MIG.

Most nations, for tariff purposes, schedule perphenazine enanthate under HS 29343090. SMILES: CCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)CL.

UNSPSC 51332864 Perphenazine enanthate is a Commodity code with minimal recent state and local procurement activity. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS posted June 30, 2026—involves procurement of naloxone and safe drug deactivation systems rather than perphenazine enanthate, indicating a significant mismatch between the code's nominal scope and the work actually being solicited. The code does not reflect active purchasing demand for the pharmaceutical product it names.

Seminole County's naloxone and drug deactivation systems IFB sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The procurement required vendors to submit electronic bids through the county's e-Procurement Portal, include all shipping and delivery costs in pricing, and comply with drug-free workplace certification and E-Verify requirements. The contract was structured as a fixed-fee two-year agreement with an optional one-year renewal and included potential FEMA funding with associated federal environmental compliance obligations. No geographic concentration or repeat buyers supporting this code's nominal scope are evident from recent activity; the single opportunity present does not align with perphenazine enanthate procurement.